

WELSH INFORMATION GOVERNANCE & STANDARDS BOARD

CDSC Notice:	CDSCN 2011 / 02
Date of Issue:	31 st March 2011

Ministerial / Official Letter: EH/ML/015/11	Subject: All Wales Oesophago-Gastric Cancer Minimum Reporting Requirements v2.0 including Core Reporting Items v5.0
Sponsor: Head of Major Health Conditions and Clinical Support Services Branch	
Implementation Date: 1 st April 2011	

CLINICAL DATA SET CHANGE NOTICE

A Clinical Data Set Change Notice (DSCN) is an information mandate for a new or revised information standard.

This CDSCN was approved by the Welsh Information Governance and Standards Board (WIGSB) at its meeting on the 17th February 2011

WIGSB Reference: IGRN 2010 / 020

Summary:

To introduce the All Wales Oesophago-Gastric Cancer Minimum Reporting Requirements v2.0 including Core Reporting Items v5.0

Data sets / returns affected:

All Wales Oesophago-Gastric Cancer Minimum Reporting Requirements v2.0

Please address enquiries about this Data Set Change Notice to the Data Standards Team in the NHS Wales Informatics Service

E-mail: data.standards@wales.nhs.uk Tel: 02920502539

The Welsh Information Governance and Standards Board is responsible for appraising information standards. Submission documents and WIGSB Outcomes relating to the approval of this standard can be found at:

<http://howis.wales.nhs.uk/sites3/page.cfm?orgid=742&pid=24632>

CLINICAL DATA SET CHANGE NOTICE

Introduction

The mandated standard has been approved by the Welsh Information Governance & Standards Board (WIGSB) for implementation with immediate effect and is referred to as the 'All Wales Oesophago-Gastric Cancer Minimum Reporting Requirements v2.0'. The standard has progressed through various review processes. The standard demonstrates the shift in focus towards outputs and details a list of reporting data items, which in its entirety produces the minimum reporting requirements for all oesophago-gastric cancers diagnosed in Wales.

The minimum reporting requirement will support the information requirements of the all Wales Clinical Steering Groups, National Cancer Standards 2005, Annual Operating Framework - cancer waiting times, participation in clinical audit and provide a key data source for the cancer registry, Welsh Cancer Intelligence & Surveillance unit (WCISU).

The standard reflects current clinical working practices and new management standards. The minimum reporting requirements has been aligned with the Welsh Data Dictionary v3.0 and, where possible, the English National Cancer Dataset Version 4.5b. Where data item definitions and permissible values are common to the Data Dictionary and/or the English National Cancer Dataset this is shown within the documentation, otherwise definitions and permissible values are specified according to the various data submission requirements.

In order to provide practical guidance to the Health Board teams supporting the collection and local use of this data, comprehensive operational support documentation has been produced for each site specific reporting requirement. This information can be accessed at <http://howis.wales.nhs.uk/sites3/page.cfm?orgid=769&pid=19419>. This should be used by Multi Disciplinary Teams, as owners of the data they collect and to implement improved data validation and verification processes thereby improving the quality of data ultimately used to improve the quality of patient care.

Actions Required

Actions for Health Boards:

- To ensure the continued routine collection of the specified data items in a timely manner. To ensure data validation processes are maintained in an ongoing drive to improve all aspects of data quality.
- To continue reporting on cancer standards, waiting time targets and any other clinical output requirement.

Actions for Cancer Information Framework:

- To ensure extracts are submitted monthly to the Welsh Cancer Intelligence & Surveillance Unit (WCISU).
- To monitor the completeness of the data items specified and nationally benchmark compliance.

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCI = Oesophago-Gastric Clinical Indicator

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0 including CORE REPORTING ITEMS V5.0

The following minimum reporting requirement contains data items to support the following outputs for submission to:

1. All Wales Steering Group: Oesophago-Gastric Cancer Clinical Indicators:
 - Median number of 15 lymph nodes examined for all resected stomach cancers
 - Median number of 10 lymph nodes examined for all resected oesophageal cancers
 - Resection rate stomach
 - Resection rate oesophagus
 - % of patients offered entry into clinical trials
 - % of patients having final pre treatment stage as agreed by the multi disciplinary team for all oesophago-gastric cancers
 - % of patients discussed by a multi disciplinary meeting
 - 5 year relative survival for curatively treated oesophago-gastric patients, stratified by stage, grade and treatment
 - % mortality rate for curatively treated oesophago-gastric surgical patents
2. National Oesophago-Gastric Cancer Audit (NOGCA)
3. Welsh Cancer Intelligence and Surveillance Unit: Cancer Registry Data Submission
4. The National Standards 2005 for Cancer Services
5. Annual Operating Framework: Cancer Waiting Times

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

Summary of Reporting Data Items:	Minimum Reporting Requirements				
	Core			Oesophago-Gastric Site Specific	
	National Cancer Standards	WCISU: Cancer Registry	AOF: CWT	NOGCA	Oesophago-Gastric Clinical Indicators
Section 1: Identification of Patient					
NHS Number	✓	✓	✓	✓	
Birth date	✓	✓		✓	
Sex	✓	✓		✓	
GP practice code	✓	✓			
Ethnic group	✓	✓			
Case record number	✓	✓			
Patient's name(s)	✓	✓		✓	
Patient's address at date of diagnosis	✓	✓			
Patient's postcode at date of diagnosis	✓	✓		✓	
Section 2: Referral					
Source of (cancer) referral	✓			✓	
Organisation code (referred to)	✓			✓	
Consultant code (referred to)	✓				
Date of receipt of cancer referral	✓				
Presentation of disease at referral	✓	✓	✓		✓
Section 3: Key Investigations					
Cancer imaging modality	✓	✓		✓	
Date of investigation	✓	✓			
Section 4: Diagnosis					
Date of diagnosis (cancer registry definition)	✓	✓		✓	✓
Basis of diagnosis (cancer registry definition)	✓	✓			
Primary cancer site	✓	✓		✓	✓
Pre-treatment morphology	✓	✓	✓	✓	
Pre-treatment staging agreed by the multi disciplinary team cT	✓	✓		✓	✓

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCI = Oesophago-Gastric Clinical Indicator

Summary of Reporting Data Items:	Minimum Reporting Requirements				
	Core			Oesophago-Gastric Site Specific	
	National Cancer Standards	WCISU: Cancer Registry	AOF: CWT	NOGCA	Oesophago-Gastric Clinical Indicators
(clinical Tumour) stage					
Pre-treatment staging agreed by the multi disciplinary team cN (clinical Node) stage	✓	✓		✓	✓
Pre-treatment staging agreed by the multi disciplinary team cM (clinical Metastasis) stage	✓	✓		✓	✓
Section 5: Multi Disciplinary Team Outcomes					
Treatment plan discussed by the multi disciplinary team	✓				✓
Multi disciplinary meeting identifier	✓				
Date treatment plan discussed by the multi disciplinary team	✓				
Cancer treatment plan intent	✓			✓	✓
Reason for no specific anti-cancer treatment	✓				
Final pre-treatment performance status agreed by the multi disciplinary team	✓	✓		✓	
Planned cancer treatment type	✓			✓	
Treatment type sequence	✓			✓	
Planned cancer treatment sub type				✓	
Section 6: Surgery					
Surgical intent		✓		✓	✓
Date on which surgical procedure(s) carried out		✓			
Surgical procedure(s) carried out		✓		✓	✓
Site code (of surgery)				✓	
Consultant code (surgeon)				✓	
Death in hospital					✓
Section 7: Pathology					
Date specimen taken		✓			

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

Summary of Reporting Data Items:	Minimum Reporting Requirements				
	Core			Oesophago-Gastric Site Specific	
	National Cancer Standards	WCISU: Cancer Registry	AOF: CWT	NOGCA	Oesophago-Gastric Clinical Indicators
Histological diagnosis		✓		✓	
Grade of differentiation		✓			✓
T (Tumour) category (pathological)		✓		✓	✓
N (Node) category (pathological)		✓		✓	✓
M (Metastasis) category (pathological)		✓		✓	✓
Proximal margin involved				✓	
Distal margin involved				✓	
Circumferential margin involved				✓	
Nodes examined number				✓	✓
Nodes positive number				✓	
Section 8: Drug Therapy					
Date treatment started (drug therapy)		✓		✓	
Treatment intent (drug therapy)		✓		✓	
Drug therapy type		✓			
Number of cycles planned				✓	
Section 9: Radiotherapy					
Date treatment started (radiotherapy)		✓		✓	
Treatment intent (radiotherapy)		✓		✓	
Radiotherapy type		✓			
Prescribed dose				✓	
Section 10: Palliative Care					
Member of specialist palliative care team seen		✓			
Section 11: Clinical Status Assessment					
Date of death		✓	✓	✓	
Section 12: AOF: Cancer Waiting Times					

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCI = Oesophago-Gastric Clinical Indicator

Summary of Reporting Data Items:	Minimum Reporting Requirements				
	Core			Oesophago-Gastric Site Specific	
	National Cancer Standards	WCISU: Cancer Registry	AOF: CWT	NOGCA	Oesophago-Gastric Clinical Indicators
Priority of referral			✓	✓	
Date of decision to treat			✓		
Date of start of first definitive procedure			✓		
First procedure			✓		
Suspension start date			✓		
Suspension end date			✓		
Reason for breach			✓		
Section 13: Clinical Trials					
Entry indicator					✓
Section 14: Endoscopy					
Consultant code (endoscopist)				✓	
Date of Endoscopic procedure(s)				✓	
Type of endoscopic procedure				✓	
Total number of data items: 70					

* Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

Version 2.0

Version	Date	Status	Author	Change Summary	Distribution
V0.2	18/09/07	Draft	JDS	Changes to include NOGCA data set items	Accepted
V0.3	20/09/07	Draft	JDS/JD	Changes to include CSCG OG cancer site specific items and RCPATH 2007 dataset revisions	Accepted
V0.4	23/09/07	Draft	JDS	Description codes & purposes checked, previous AUGIS items deleted & first draft numbering of OG items	Accepted
V0.5	26/09/07	Draft	JDS	Above completed to conform to NHS Data Dictionary or NHS Wales Data Dictionary	Consultation – UGI Steering Group
V0.6	27/09/07	Draft	JD	Updated changes in line with comments from consultation	
V0.7	28/09/07	Draft	JDS	Minor changes to pathology and follow-up	Consultation – UGI Steering Group
V0.8	03/01/08	Draft	JDS	Major changes, updated to WIGSB Nov 2007 core V3 and NOGCA V2.6 Sept 2007	Review – JD
V0.9	16/01/08	Draft	JDS	Cardiac function item added	
V1.0	12/02/08	Draft	JDN	Formatting alterations, updated inline with comments from Consultant	Review – JD/JDS
V1.1	28/02/08	Draft	JDN	Major changes, updated to Core V3.4	Review – JD/JDS
V1.2	04/03/08	Draft	JDN	Major changes, updated to Core V4	Review – JD/JDS
V1.3		Draft	JDN	Updated to OG RCPATH dataset requirements	Review – JD/JDS
V1.4	07/05/08	Draft	JDN	Changes, updated to Core V4 Final	Review – JD/JDS
V1.5	12/08/08	Draft	JDN	Removal of RCPATH site specific items awaiting further information from CHIRP project.	Review – Steering Group Lead

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCI = Oesophago-Gastric Clinical Indicator

Version	Date	Status	Author	Change Summary	Distribution
V1.6	07/04/09	Draft	JDN/JM	Updates including coding of ICD10 and OPCS4	Review – Steering Group Lead
V1.7	29/09/10	Draft	JDN	Updated to reflect Final Core Clinical Minimum Reporting Requirements V5.0 and mapped to the All Wales Gastro Oesophageal reporting and data collection requirements.	Review – Tom Crosby/Anne Hughes
V1.8	11/10/10	Draft	JDN/TC	Updates to documentation after consultation	Review – Tom Crosby/Ann Hughes
V1.9	25/10/10	Draft	JDN/TC	Updates to documentation after 2 nd consultant	Review – Tom Crosby/Ann Hughes
V2.0	20/12/10 – 01/02/11	Final	JDN	Updates as per WIGSB / DSCN sub group comments	Final – publication

Name	Date
WIGSB	18/11/10
DSCN Sub Group	

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCI = Oesophago-Gastric Clinical Indicator

1. IDENTIFICATION OF PATIENT	11
2. REFERRAL	15
3. KEY INVESTIGATIONS	19
4. DIAGNOSIS	20
5. MULTI DISCIPLINARY TEAM OUTCOMES	25
6. SURGERY	30
7. PATHOLOGY	33
8. DRUG THERAPY [including chemotherapy, hormone and biological agents]	36
9. RADIOTHERAPY	38
10. PALLIATIVE CARE	40
11. CLINICAL STATUS ASSESSMENT	41
12. ANNUAL OPERATING FRAMEWORK: CANCER WAITING TIMES	42
13. CLINICAL TRIALS	46
14. ENDOSCOPY	47

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCI = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
1. IDENTIFICATION OF PATIENT				
1.0 ENCDv4.5b (1.1) SPCDv1.0 (1.1) NOGCA	NHS number	Used for unique identification to match records from different providers. To allow 'tracking' through the clinical pathway.	It is mandatory to record the NHS number for each patient. The NHS number is allocated to an individual, to enable unique identification for NHS health care purposes.	NHS Wales Data Dictionary
1.1 ENCDv4.5b (1.10) SPCDv1.0 (1.2) NOGCA	Birth date	Used for unique identification to match records from different providers. Used to enable age at diagnosis to be established for epidemiological and survival analyses.	Date of birth of patient.	NHS Wales Data Dictionary
1.2 ENCDv4.5b (1.9) SPCDv1.0 (1.3) NOGCA	Sex	Used for unique identification to match records from different providers. Used to enable sex to be established for survival analysis. Assists in the correct identification of gender specific primary cancer sites.	This is the sex of person, employee or patient.	NHS Wales Data Dictionary <ul style="list-style-type: none"> • Male • Female • Not specified

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
1. IDENTIFICATION OF PATIENT [continued]				
1.3 ENCDv4.5b (1.12) SPCDv1.0 (1.4)	GP practice code	To enable analysis by GP practice code. To enable the healthcare professionals to contact the GP practice and share patient information.	A code which uniquely identifies the GP Practice of the GP. Code as listed for Practices in Wales. These are updated monthly by the Information Products Unit of HSW with information supplied by the Organisation Data Service (ODS) and can be viewed on the Health Reference Data Web Pages on HOWIS.	NHS Wales Data Dictionary
1.4 ENCDv4.5b (1.15) SPCDv1.0 (1.5)	Ethnic group	To enable analysis by ethnicity.	This is the ethnic group of the patient, as selected by the patient. The patient is the arbiter of the information. Classifications are based on the 14+1 new ethnic group data categories used in the 2001 Census and the information recorded about ethnic group must be obtained by asking the patient.	NHS Wales Data Dictionary <ul style="list-style-type: none"> • Any white background • Mixed white and black Caribbean • Mixed white and black African • Mixed white and Asian • Any other mixed background • Indian and British Indian • Pakistani or British Pakistani • Bangladeshi or British Bangladeshi • Any other Asian background (other than Chinese) • Black Caribbean or black British Caribbean • Black African of black British African • Any other black background • Chinese • Any other ethnic group • Not stated

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
1. IDENTIFICATION OF PATIENT [continued]				
1.5 ENCDv4.5b (1.2) SPCDv1.0 (2.1)	Case record number	Used for unique identification to link events within a single service provider. To allow 'tracking' through the clinical pathway.	This is the patient's case record number which is unique to that patient within a hospital or health care provider.	NHS Wales Data Dictionary
1.6 ENCDv4.5b (1.5 & 1.6) NOGCA	Patient's name(s)	Used for unique identification to link records where the new NHS number is not available. To assist 'tracking' through the clinical pathway.	This will be the patient's preferred name. The patient is the arbiter of his/her name.	NHS Wales Data Dictionary
1.7 ENCDv4.5b (1.7)	Patient's address at date of diagnosis	Used to enable the address at diagnosis to be established for epidemiological and survival analyses.	This is the usual address nominated by the patient at the time of admission or attendance. If patients usually reside elsewhere are staying in hotels, hostels or other residential establishments for a short term, say a week, they should be recorded as staying at their usual place of residence. However if long term, such as at boarding school, the school address must be recorded. University students may nominate either their home address or the address of their university accommodation. Where patients are not capable of supplying	NHS Wales Data Dictionary

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
1. IDENTIFICATION OF PATIENT [continued]				
			<p>this information, because of age or mental illness, for example, then the person responsible for the patient, such as a parent or guardian, should nominate the usual address. Patients not able to provide an address should be asked for their most recent address. If this cannot be established then you should record the address as 'No fixed abode' or 'Address unknown'. These patients are regarded as resident in the local geographical district for contracting purposes. For birth episodes this should refer to the mother's usual place of residence.</p>	
1.8 ENCDv4.5b (1.8) NOGCA	Patient's postcode at date of diagnosis	Used to enable the postcode at diagnosis to be established for epidemiological and survival analyses.	The postcode applied to the usual address nominated by the patient at the time of admission or attendance, using rules supplied under the data item POSTCODE and those in the NHS Postcode User Directory.	NHS Wales Data Dictionary

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
2. REFERRAL				
2.0 ENCDv4.5b (2.1) SPCDv1.0 (6.1) NOGCA	Source of (cancer) referral	To allow 'tracking' through the clinical pathway, to identify patterns of referral and to assist in audit and waiting times monitoring.	This is a classification which is used to identify the source of referral of each episode or referral.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> • Following an emergency admission (includes all acute admissions via A&E (Accident & Emergency), Medical Admissions Unit, etc.) • Following a domiciliary visit by the consultant • Referral from General Medical Practitioner (for out-patient or other non-emergency referrals) • Referral from out-patients by a consultant, other than in an A&E department • Referral of an in-patient by a Consultant • Referral from screening services • Self-referral (i.e. the patient was not seen previously by a GP) • Other source of referral (will include referrals from Private

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
2. REFERRAL [continued]				
				Healthcare) <ul style="list-style-type: none"> • Following an A&E attendance (i.e. an out-patient clinic attendance after an A&E visit) • General Dental Practitioner • Community Dental Service • Not known
2.1 ENCDv4.5b (1.3) SPCDv1.0 (2.2) NOGCA	Organisation code (referred to)	To monitor the proportion of cancer patients referred to a cancer site specialist or cancer site specific team. To be able to report by hospital code.	Unique identifier for each organisation or site within an organisation.	NHS Wales Data Dictionary
2.2 ENCDv4.5b (2.7) SPCDv1.0 (6.2)	Consultant code (referred to)	To monitor the proportion of cancer patients to each cancer site specialist.	This item relates to the consultant to whom the referral is made and who is responsible for the overall care of the patient. If the referral is to a team, then this refers to the first consultant seen. This item uses the nationally agreed form for consultant code or Independent Nurse. It is the General Medical Council (GMC) code for the Consultant or the GP acting as a Consultant or locum Consultant , which is the unique identifier. The nurse's	NHS Wales Data Dictionary

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
2. REFERRAL [continued]				
			Registration Number will be used to identify the Independent Nurse.	
2.3 ENCDv4.5b (2.6)	Date of receipt of cancer referral	To establish the start date for the specialist-based diagnosis and management process. To identify length of delay in the handling or referrals. Audit for standards and monitoring Cancer Waiting time targets.	<p>The date that the referral request is received by the provider. [Applies to all referral routes, not just from primary care]</p> <ul style="list-style-type: none"> • Date when letter/fax/electronic form is received. In the case of a written referral, this should be the date on which the letter or fax arrived in the hospital. The most likely source of this date will be a date stamp of the receiving department on the referral letter. • Date of verbal request. • Date of admission to hospital in the case of patients admitted as an emergency • The date of the first out-patient appointment, if the referral was a self referral. 	
2.4 ENCDv4.5b (2.13) GOCl	Presentation of disease at referral	Facilitates the algorithm utilised to support Annual Operating Framework data collection and submission.	<p>Indicates the presentation of the disease at referral. Definitions of the permissible values are as follows:</p> <ul style="list-style-type: none"> • New diagnosis: patients referred at the time of the initial diagnosis 	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
2. REFERRAL [continued]				
			<ul style="list-style-type: none"> • Recurrent disease: patients referred at the time of recurrent disease (previous radical treatment with a disease free interval) • Longstanding disease: patients who have longstanding disease cared for by another specialist and recently referred for an oncologist opinion. • Other; to be used when none of the above apply i.e. if a patient moves into the area but has already received radical treatment elsewhere and is currently disease free and referred for follow-up only. 	<p>will be kept under review.</p> <ul style="list-style-type: none"> • New diagnosis* <ul style="list-style-type: none"> - screen detected - clinically detected • Recurrent disease • Long-standing disease • Other <p>*Additional permissible values for 'New diagnosis' will be dependant upon the tumour sites inclusion to the 'National Screening Programme'.</p>

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
3. KEY INVESTIGATIONS				
3.0 ENCDv4.5b (3.3) NOGCA	Cancer Imaging modality	To estimate the level of accuracy of the diagnosis and staging when accounting for casemix and outcome analysis. Required for the use of the Multi Disciplinary Meeting (MDM) module.	The types of investigations performed to diagnose and stage the patient.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review.
3.1 ENCDv4.5b (3.2)	Date of investigation	Required for audit of the national Cancer Standards, and the use of the Multi Disciplinary Meeting (MDM) module.	The date the investigation was performed.	

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCI = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
4. DIAGNOSIS				
4.0 ENCDv4.5b (4.1) NOGCA GOCI	Date of diagnosis (cancer registry definition)	To calculate annual incidence rates and to determine the start date for survival analysis by the cancer registry.	The definition provided conforms with the requirements specified by the Cancer Registry. The date of the first event (of the seven listed under permissible values) to occur chronologically should be chosen as the incidence date. If an event of higher priority occurs within three months of the date initially chosen, the date of the higher priority event should take precedence, this should also be reflected and updated in the 'Basis of diagnosis'.	WCISU (Welsh Cancer Intelligence and Surveillance Unit) Cancer Registry Order of declining priority: 1 – Date of first histological or cytological confirmation of this malignancy (with the exception of histology or cytology at autopsy). This date should be, in the following order: a – date when the specimen was taken b – or date of receipt by the pathologist c – or date of the pathology report 2 – Date of imaging x-ray or scan which confirms this malignancy 3 – Date of clinical diagnosis by consultant confirming malignancy 4 – Date of outpatient evaluation or in-patient hospital admission for a confirmed malignancy 5 – Date of diagnosis, other than 1 – 4, e.g. GP clinical diagnosis 6 – Date of death, if no information is available other than the fact that the patient has died because of malignancy. 7 – Date of death, if the malignancy is discovered at autopsy.

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
4. DIAGNOSIS [continued]				
4.1 ENCDv4.5b (4.4)	Basis of diagnosis (cancer registry definition)	To establish the validity of the date of diagnosis recorded.	The definition provided conforms with the requirements specified by the Cancer Registry. As a measure of validity, only the ' <u>most valid basis of diagnosis</u> ' is required. The codes opposite are hierarchical, therefore the higher the number the more validity the basis holds. If an event of higher priority occurs within three months of the date of diagnosis, the basis of the higher priority event should take precedence.	WCISU (Welsh Cancer Intelligence and Surveillance Unit) Cancer Registry Non-microscopic 1 – Death Certificate (The only information available is from a death certificate) 2 – Clinical (Diagnosis made before death but without the benefit of any of the following (2- 7)) 3 – Clinical Investigation (Includes all diagnostic techniques (e.g. X-rays, endoscopy, imaging, ultrasound, exploratory surgery and autopsy) without a tissue diagnosis) 4 – Specific tumour markers (Includes biochemical and/or immunological markers which are specific for a tumour site) Microscopic 5 – Cytology (Examination of cells whether from a primary or secondary site, including fluids aspirated using endoscopes or needles. Also including microscopic examination of peripheral blood films and trephine bone marrow aspirates). 6 – Histology of a metastases (Histological examination of tissues)

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
4. DIAGNOSIS [continued]				
				from a metastasis, including autopsy specimens) 7 – Histology of a primary tumour (Histological examination of tissue from the primary tumour, however obtained, including all cutting and bone marrow biopsies. Also includes autopsy specimens of a primary tumour) 0 – Unknown (No information on how the diagnosis has been made (e.g. Patient Administration System (PAS) or Hospital Information Support System (HISS) record only)
4.2 ENCDv4.5b (4.2) SPCDv1.0 (5.1) NOGCA NOCI	Primary cancer site	To establish the numbers of various cancers to enable calculation of annual incidence rates. To allow for an assessment of subsequent treatment and outcome rates.	The site of the primary cancer for which the patient is receiving care.	Refer to the current version of the International Statistical Classification of Diseases and Health Related Problems (ICD10). *Permissible grouped values and labels will be dependant upon the output specifications.
4.3 NOGCA	Pre-treatment morphology	To record the definitive behaviour/histology of the tumour at the point of diagnosis.	Cell type of malignant disease determined before the start of treatment.	Refer to morphology code as in the extract of the International Classifications of Diseases for Oncology on "Morphology of

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
4. DIAGNOSIS [continued]				
				neoplasms" in ICD10. *Permissible grouped values and labels will be dependant upon the output specifications.
4.4 ENCDv4.5b (6.1) NOGCA GOCl	Pre-treatment staging agreed by the multi disciplinary team cT (clinical Tumour) stage	To allow for the Final pre treatment staging by the multi disciplinary team to be taken into account in the analysis of treatment and outcome.	The 'T' (tumour) part of the TNM (Tumour, Node and Metastasis) classification to describe the clinical stage of the tumour prior to treatment. Clinical classification (Pre-treatment clinical classification), designated cTNM. This is based on evidence acquired before treatment. Such evidence arises from physical examination, imaging, endoscopy, biopsy, surgical exploration and other relevant examinations. If the malignancy is discovered only at autopsy, or via a death certificate, then no pre-treatment TNM stage will be recorded.	Refer to UICC (International Union Against Cancer) TNM (Tumour, Node and Metastasis) Classifications of Malignant Tumours
4.5 ENCDv4.5b (6.3) NOGCA GOCl	Pre-treatment staging agreed by the multi disciplinary team cN (clinical Node) stage	To allow for the Final pre treatment staging by the multi disciplinary team to be taken into account in the analysis of treatment and outcome.	The 'N' (Node) part of the TNM (Tumour, Node and Metastasis) classification to describe the clinical stage of the tumour prior to treatment. Clinical classification (Pre-treatment clinical classification), designated	Refer to UICC (International Union Against Cancer) TNM (Tumour, Node and Metastasis) Classifications of Malignant Tumours

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
4. DIAGNOSIS [continued]				
			<p>cTNM. This is based on evidence acquired before treatment. Such evidence arises from physical examination, imaging, endoscopy, biopsy, surgical exploration and other relevant examinations.</p> <p>If the malignancy is discovered only at autopsy, or via a death certificate, then no pre-treatment TNM stage will be recorded.</p>	
4.6 ENCDv4.5b (6.5) NOGCA NOGCI	Pre-treatment staging agreed by the multi disciplinary team cM (clinical Metastasis) stage	To allow for the Final pre treatment staging by the multi disciplinary team to be taken into account in the analysis of treatment and outcome.	<p>The 'M' (Metastasis) part of the TNM (Tumour, Node and Metastasis) classification to describe the clinical stage of the tumour prior to treatment.</p> <p>Clinical classification (Pre-treatment clinical classification), designated cTNM. This is based on evidence acquired before treatment. Such evidence arises from physical examination, imaging, endoscopy, biopsy, surgical exploration and other relevant examinations.</p> <p>If the malignancy is discovered only at autopsy, or via a death certificate, then no pre-treatment TNM stage will be recorded.</p>	Refer to UICC (International Union Against Cancer) TNM (Tumour, Node and Metastasis) Classifications of Malignant Tumours

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
5. MULTI DISCIPLINARY TEAM OUTCOMES				
5.0 ENCDv4.5b (5.1) GOCl	Treatment plan discussed by the multi disciplinary team	Required for the audit of National Cancer Standards 2005 and required for the use of the Multi Disciplinary Meeting (MDM) module.	To record the fact that the care of this patient was formally reviewed by a specialist team.	<ul style="list-style-type: none"> • Yes • No
5.1	Multi disciplinary meeting identifier	This item is required to audit against the National Cancer Standards 2005). Enables effective use of the Multi Disciplinary Meeting (MDM) module to facilitate direct patient care plans and validates data collection at source.	The operating identifier of the multi disciplinary meeting where the patient was discussed.	
5.2 ENCDv4.5b (5.2)	Date treatment plan discussed by the multi disciplinary team	Required for the audit of the National Cancer Standards and submission to National / Welsh audits required for the use of the Multi Disciplinary Meeting (MDM) module.	The date that cancer care plan was discussed by the specialist team. The date of the discussed treatment plan (of the three listed under permissible values) will be utilised in order (where more than one permissible value is listed) as per the required output specifications.	Cancer Standards 2005 <ul style="list-style-type: none"> • Date of the first treatment plan discussion National / Welsh audits <ul style="list-style-type: none"> • Date treatment plan discussed, indicated as the most significant by the multi disciplinary team • Date of the last treatment plan discussion

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
5. MULTI DISCIPLINARY TEAM OUTCOMES [continued]				
5.3 ENCDv4.5b (5.5) NOGCA GOCl	Cancer treatment plan intent	To monitor treatment outcomes against local clinical policies and guidelines. To enable analysis of treatment planned versus treatment given. To monitor the number of cancer patients who received no specific anti-cancer treatment. This item is also required for the use of the multi Disciplinary Meeting (MDM) module.	<p>The intention of the treatment which is planned for the patient at this point in time. It is appreciated that this decision may change as treatment is given and the patient's response to this treatment is assessed. Definitions of the permissible values are as values:</p> <ul style="list-style-type: none"> • Curative Treatment given with the potential for cure (radical treatment) even if the proportion of patients achieving long term disease control (> 2 years) is small • Palliative anti-cancer treatment given with the aim of symptom control. (Palliative intent relates to all intended palliative treatments and not just treatments intended to be delivered by the specialist palliative care team) • Supportive treatment To sustain the patients and carers ability to cope with a chronic or deteriorating condition and including respite care • No specific anti-cancer treatment 	<p>Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review.</p> <ul style="list-style-type: none"> • Curative • Palliative • Supportive treatment • No specific anti-cancer treatment

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
5. MULTI DISCIPLINARY TEAM OUTCOMES [continued]				
5.4 ENCDv4.5b (5.8)	Reason for no specific anti-cancer treatment	To monitor the reasons why cancer patients received no specific anti-cancer treatment. For the audit of the National Cancer Standards 2005 and is also required for the use of the Multi Disciplinary Meeting (MDM) module.	The reason why the patient did not receive any specific anti-cancer treatment. The permissible value 'Unfit: poor performance status' is dependent upon the output value for the 'Final pre-treatment performance status agreed by the multi disciplinary team'.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> • Patient declined treatment • Unfit: poor performance status • Unfit: significant co-morbidity • Unfit: advanced stage cancer • Unknown Primary Site • Died before treatment • No anti-cancer treatment available • Other • Watchful waiting • Reason not known [multiple responses possible]
5.5 ENCDv4.5b (5.10) NOGCA	Final pre-treatment performance status agreed by the multi disciplinary team	To allow for performance status to be taken into account in treatment decisions and in the analysis of treatment and outcome. This item is also required for the use of the Multi Disciplinary Meeting (MDM) module.	The patients' performance status prior to treatment. If the permissible value is high and no anti-cancer treatment is given based on this value, it should be reflected in the reporting data item 'Reason for no specific anti-cancer treatment' and the permissible value 'Unfit: poor performance status' reported.	Refer to the WHO (World Health Organisation) / ECOG (Eastern Cooperative Oncology Group) scoring system

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
5. MULTI DISCIPLINARY TEAM OUTCOMES [continued]				
5.6 ENCDv4.5b (5.6) NOGCA	Planned cancer treatment type	To determine the number of patients offered primary treatment types. To determine patterns of planned versus actual primary treatment types. To enable analysis of discrete groups of patients particularly where several modalities are planned. This item is also required for the use of the MDM module.	The type(s) of cancer treatments that is planned for the patient.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> • Surgery • Teletherapy • Chemotherapy • Hormone therapy • Specialist palliative care • Brachytherapy • Biological • Active monitoring • Other <p>[multiple responses possible]</p>
5.7 ENCDv4.5b (5.7) NOGCA	Treatment type sequence	To determine patterns of planned primary treatment types. This item is also required for the use of the Multi Disciplinary Meeting (MDM) module.	The sequence in which the planned cancer treatment will be given. Planned treatment types are assigned a sequence number, the number will relate to the order the treatment is planned to be given e.g. radiotherapy 1, radiotherapy will be the first planned treatment. surgery 2. surgery will be the second planned treatment etc. For concurrent treatments such as chemo-	<ul style="list-style-type: none"> • 1 • 2 • 3 • 4 • 5

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
5. MULTI DISCIPLINARY TEAM OUTCOMES [continued]				
			radiotherapy both treatments should be assigned the same sequence number e.g. chemotherapy 1 and radiotherapy 1.	
5.8 NOGCA	Planned cancer treatment sub type	To determine the number of patients offered primary treatment types. To determine patterns of planned versus actual primary treatment types. To enable analysis of discrete groups of patients particularly where several modalities are planned. Linked with reporting item 5.6 'Planned cancer treatment type' to specify other relevant planned treatment types. Required for submission to the national oesophago-gastric cancer audit.	The specified other type(s) of cancer treatment that is planned for the patient.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> Endoscopic mucosal resection Photodynamic therapy Endoscopic palliative therapy: unspecified

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
6. SURGERY				
6.0 ENCDv4.5b (7.4) NOGCA GOCl	Surgical intent	To enable analysis by surgical intent.	The purpose of the surgical procedure(s) being carried out.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> • Diagnostic • Staging • Curative • Palliative
6.1 ENCDv4.5b (7.9) NOGCA	Date on which surgical procedure(s) started	<p>Diagnostic and staging procedures</p> <ul style="list-style-type: none"> • To estimate the level of accuracy of the diagnosis and staging when accounting for casemix and outcome analysis. <p>Curative and palliative procedures</p> <ul style="list-style-type: none"> • To identify the date diagnostic and staging procedures were performed. To determine the time interval between referral and diagnosis by the specialist team and the start of treatment. Required to be able to measure survival time from the start of treatment. To enable the date of first definitive treatment to be recorded. 	The date on which the surgical procedure was performed.	

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
6. SURGERY [continued]				
6.2 ENCDv4.5b (7.10 & 7.11) NOGCA GOCl	Surgical procedure(s) carried out	To determine type of surgery performed to enable analysis of surgically related data. To measure the effectiveness of surgical procedures performed and to be used as a measure for survival.	The type of procedure performed.	See the current version of the Office of Population, Censuses and Surveys Classification of Surgical Operations and Procedures (OPCS) of interventions and procedures. *Permissible grouped values and labels will be dependant upon the output specifications.
6.3 NOGCA	Site code (of surgery)	To enable surgical analysis by organisation / surgical centre. Required for submission to the national clinical cancer audits.	The organisation code for the site where the patient is treated.	NHS Data Dictionary
6.4 NOGCA	Consultant code (surgeon)	To enable surgical analysis by consultant responsible for the operation. Required for submission to the national oesophago-gastric cancer audit.	This item relates to the consultant surgeon who has overall surgical responsibility for the patient and operations performed. This may or may not be the same consultant as the consultant (referred to)). This item uses the nationally agreed form for consultant code or Independent Nurse. It is the General Medical Council (GMC) code for the Consultant or the GP acting as a Consultant or locum Consultant, which is the unique identifier. The nurse's Registration Number will be used to identify the Independent Nurse.	NHS Wales Data Dictionary

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
6. SURGERY [continued]				
6.5 GOCl	Death in hospital	To monitor the proportion of deaths for surgically treated patients. Required for submission to the national oesophago-gastric cancer audit.	Indicates whether the patient died in hospital following surgical treatment.	<ul style="list-style-type: none"> • Yes • No

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
7. PATHOLOGY				
7.0	Date specimen taken	Details the date the pathological specimen was taken to enable cross-referencing with the surgical procedures performed.	The date on which the specimen was extracted.	
7.1 ENCDv4.5b (8.10) NOGCA	Histological diagnosis	To determine the incidence of tumours of different histology and behaviour for epidemiological purposes.	A morphology code providing increased specificity for neoplasm recorded under diagnosis.	Refer to morphology code as in the extract of the International Classifications of Diseases for Oncology on "Morphology of Neoplasms" in ICD10. *Permissible grouped values and labels will be dependant upon the output specifications.
7.2 ENCDv4.5b (8.11) GOCl	Grade of differentiation	Prognostic factor. This field records the histopathological grade of the tumour as found in the specimen presented for examination. In tumours containing several areas of different grade, the grade of the predominant component should be recorded. For the majority of tumours (squamous carcinomas, adenosquamous carcinomas, adenocarcinomas and transitional cell carcinomas) the UICC (International Union Against Cancer) differentiation grading system should be used. Also enables survival analysis i.e. survival by grade.	Qualitative assessment of the differentiation of the tumour expressed as the extent to which a tumour resembles the normal tissue at that site.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> • Grade of differentiation is not appropriate or cannot be assessed • Well differentiated • Moderately differentiated • Poorly differentiated • Undifferentiated/anaplastic

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
7. PATHOLOGY [continued]				
7.3 ENCDv4.5b (8.16) NOGCA GOCl	T (Tumour) category (pathological)	To allow for the pathological T (Tumour) stage to be taken into account in the analysis of treatment and outcome.	Post surgical staging: the extent of the primary tumour after excision of the primary cancer. This is derived from Local Invasion - Tumour Extent and Structure (s) Invaded data items on the Pathology dataset.	Refer to UICC (International Union Against Cancer) TNM (Tumour, Node and Metastasis) Classifications of Malignant Tumours
7.4 ENCDv4.5b (8.17) NOGCA GOCl	N (Node) category (pathological)	To allow for the pathological N (Node) stage to be taken into account in the analysis of treatment and outcome.	The histological evidence of the absence or presence and extent of regional lymph node metastases. This is derived from Local/Regional nodes positive, Other Nodes positive and Marker lymph node 1 positive data items on the Pathology dataset.	Refer to UICC (International Union Against Cancer) TNM (Tumour, Node and Metastasis) Classifications of Malignant Tumours
7.5 ENCDv4.5b (8.18) NOGCA GOCl	M (Metastasis) category (pathological)	To allow for the pathological M (Metastasis) stage to be taken into account in the analysis of treatment and outcome.	The histological evidence of the absence or presence of distant metastases. This is derived from the Distant Metastases data item on the Pathology dataset.	Refer to UICC (International Union Against Cancer) TNM (Tumour, Node and Metastasis) Classifications of Malignant Tumours
7.6 NOGCA	Proximal margin involved	To determine the adequacy of the excision. Required for submission to the national oesophago-gastric cancer audit.	The minimum distance from the proximal specimen margin to tumour is measured from histological slides. If this is less than or equal to 1 mm the margin is by definition involved.	<ul style="list-style-type: none"> • Yes • No

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCI = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
7. PATHOLOGY [continued]				
7.7 NOGCA	Distal margin involved	To determine the adequacy of the excision. Required for submission to the national oesophago-gastric cancer audit.	The minimum distance from the distal specimen margin to tumour is measured from histological slides. If this is less than or equal to 1 mm the margin is by definition involved.	<ul style="list-style-type: none"> • Yes • No
7.8 NOGCA	Circumferential margin involved	To determine the adequacy of the excision. Required for submission to the national oesophago-gastric cancer audit.	The minimum distance from the circumferential specimen margin to tumour is measured from histological slides. If this is less than or equal to 1 mm the margin is by definition involved.	<ul style="list-style-type: none"> • Yes • No
7.9 NOGCA GOCI	Nodes examined number	To determine the number of lymph nodes examined in resected specimens. Required for submission to the national oesophago-gastric cancer audit.	The number of local/regional lymph nodes examined and reported. Local/regional nodes are defined by the UICC (International Union Against Cancer) TNM (Tumour, Node and Metastasis) Atlas and vary with the primary cancer site	
7.10 NOGCA	Nodes positive number	To determine the number of positive lymph nodes in resected specimens. Required for submission to the national oesophago-gastric cancer audit.	The number of local/regional lymph nodes reported as being positive for the presence of tumour metastases. Local/regional nodes are defined by the UICC (International Union Against Cancer) TNM (Tumour, Node and Metastasis) Atlas and vary with the primary cancer site.	

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCI = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
8. DRUG THERAPY [including chemotherapy, hormone and biological agents]				
8.0 ENCDv4.5b (9.10) NOGCA	Date treatment started (drug therapy)	To determine the time interval between referral and diagnosis by the specialist team and the start of treatment. Required to be able to measure survival time from the start of treatment. To enable the date of first definitive treatment to be recorded.	The date on which the drug therapy was first administered.	
8.1 ENCDv4.5b (9.8) NOGCA	Treatment intent (drug therapy)	To establish the frequency of different treatment intents. To monitor treatment related outcomes. To assess patterns of chemotherapy or other drug therapy practice for comparison with best practice guidelines.	The intended outcome of the drug therapy to be administered.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> • Adjuvant • Neoadjuvant • Radical (curative) • Palliative
8.2 ENCDv4.5b (9.7)	Drug therapy type	To establish patterns of drug therapy treatment.	The type of drug therapy administered.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> • Chemotherapy • Hormone / endocrine therapy

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
8. DRUG THERAPY [including chemotherapy, hormone and biological agents] [continued]				
				<ul style="list-style-type: none"> Immunotherapy Bisphosphonate therapy Other
8.3 NOGCA	Number of cycles planned	To establish patterns of planned drug therapy cycles. Required for submission to the national oesophago-gastric cancer audit.	The number of drug therapy cycles the patient was intended to receive (as decided pre-treatment).	Cycles in numeric units

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
9. RADIOTHERAPY				
9.0 ENCDv4.5 b (10.8) NOGCA	Date treatment started (radiotherapy)	To determine the time interval between referral and diagnosis by the specialist team and the start of treatment. Required to be able to measure survival time from the start of treatment. To enable the date of first definitive treatment to be recorded.	The date on which the radiotherapy first administered.	
9.1 ENCDv4.5 b (10.6) NOGCA	Treatment intent (radiotherapy)	To assess patterns of radiotherapy practice for comparisons with best practice guidelines.	The intended outcome of the radiotherapy to be administered.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> • Adjuvant • Neoadjuvant • Radical (curative) • Palliative
9.2	Radiotherapy type	This data item is required to distinguish which type of radiotherapy is administered to a patient.	The type of radiotherapy administered.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> • Teletherapy • Brachytherapy

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
9. RADIOTHERAPY [continued]				
9.4 NOGCA	Prescribed dose	To establish patterns of prescribed radiotherapy doses. Required for submission to the national oesophago-gastric cancer audit.	The prescribed dose of radiotherapy the patient was intended to receive (as decided pre-treatment)	Fractions in numeric units

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
10. PALLIATIVE CARE				
10.0	Member of specialist palliative care team seen	This item is required to audit against the national Cancer Standards 2005.	Has the patient seen a member of the specialist palliative care team?	<ul style="list-style-type: none"> • Yes • No

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
11. CLINICAL STATUS ASSESSMENT				
11.0 ENCDv4.5 b (15.1) SPCDv1.0 (9.1) NOGCA	Death date	To determine survival rates and mortality rates.	Date of patient's death.	NHS Wales Data Dictionary

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCI = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
12. ANNUAL OPERATING FRAMEWORK: CANCER WAITING TIMES				
12.0 ENCDv4.5b (2.4) SPCDv1.0 (6.5) NOGCA	Priority of referral	Facilitates the algorithm utilised to support Annual Operating Framework data collection and submission.	This is the priority of a request for services and is to be recorded for a new patient, that is, First Attendance = 1 In the case of services to be provided by a Consultant, it is as assessed by or on behalf of the Consultant.	NHS Wales Data Dictionary 1 – Urgent referral for suspected cancer from a General Medical Practitioner or General Dental Practitioner, classified by consultant 2 – Other referral source or urgency, classified by consultant
12.1	Date of decision to treat	Required for the audit of the national cancer waiting times. To measure the waiting time between date of diagnosis (date of decision to treat) and first definitive treatment for non-urgent suspected cancer patients.	The date upon which the decision to treat was confirmed between a designated member of the multi disciplinary team and the patient.	Refer to Welsh Health Circular (WHC(2004)067) & CSCG (Cancer Services Coordinating Group) Cancer Waiting Times Query Log
12.2	Date of start of first definitive procedure	To determine the time interval between referral and diagnosis by the specialist team and the start of treatment. Required to be able to measure survival time from the start of treatment. To enable the date of first definitive treatment to be recorded.	Date of start of the first definitive procedure which may be surgery (not examination under anaesthetic which is considered staging), radiotherapy, drug therapy, specialist palliative care etc. It is also reported in addition to the surgery, radiotherapy and drug therapy start date data items.	Refer to Welsh Health Circular (WHC(2004)067) & CSCG (Cancer Services Coordinating Group) Cancer Waiting Times Query Log
12.3	First procedure	To support the tracking of patients, adhering to the requirements of the Annual Operating Framework: Cancer Waiting Times.	The type of the first procedure which may be surgery (not examination under anaesthetic which is considered staging), radiotherapy, drug therapy, specialist palliative care etc. It is also reported in addition to the surgery,	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
12. ANNUAL OPERATING FRAMEWORK: CANCER WAITING TIMES [continued]				
			radiotherapy and drug therapy type data items.	will be kept under review. <ul style="list-style-type: none"> • Surgery • Radiotherapy • Chemotherapy • Hormone therapy • Specialist palliative care • Biological • Brachytherapy • Active monitoring • Other
12.4	Suspension start date	Details planned treatment information used to manage patient care and service delivery to comply with cancer waiting times.	This allows the start of a period of suspension to be recorded.	Refer to Welsh Health Circular (WHC(2004)067) & CSCG (Cancer Services Coordinating Group) Cancer Waiting Times Query Log
12.5	Suspension end date	Details planned treatment information used to manage patient care and service delivery to comply with cancer waiting times.	This allows the end of a period of suspension to be recorded.	Refer to Welsh Health Circular (WHC(2004)067) & CSCG (Cancer Services Coordinating Group) Cancer Waiting Times Query Log
12.6	Reason for breach	Analysis is required at Health Board, Network, and Regional and National level on reasons why patients breach cancer waiting times. A picklist was compiled after consultation with cancer waiting times staff in all Health Boards in Wales, English (Data Set Change Notice) DSCN22/2002 and was approved by the Welsh Assembly Government –	The reason why the patient was not treated within the required treatment times according to the cancer waiting times standards.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> • Clinic cancellation • Outpatient capacity inadequate • Administrative delay

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
12. ANNUAL OPERATING FRAMEWORK: CANCER WAITING TIMES [continued]				
		Cancer Waiting Times Advisory sub-group.		<ul style="list-style-type: none"> Elective IP (in-patient) cancellation by Trust (non- medical reason) Elective IP cancellation by Trust: no ward beds available (patient unable to be scheduled for treatment within target time) Elective IP cancellation by Trust: no HDU (high dependency unit) beds available (patient unable to be scheduled for treatment within target time) Elective IP cancellation by Trust: no ITU (intensive therapy unit) beds available (patient unable to be scheduled for treatment within target time) Elective IP cancellation by Trust: no theatre time available (patient unable to be scheduled for treatment within target time) Delay to diagnostic test(s) – delay caused by wait for diagnostic test(s) Complex diagnostic pathway (many or complex, diagnostic tests required) Delay in patient pathway due to referral between Trusts for radiotherapy

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
12. ANNUAL OPERATING FRAMEWORK: CANCER WAITING TIMES [continued]				
				<ul style="list-style-type: none"> Delay in patient pathway due to referral for in house chemotherapy Delay in patient pathway due to referral for tertiary chemotherapy Delay in patient pathway due to referral for in house surgery Delay in patient pathway due to referral for tertiary surgery Delay in patient pathway due to referral between Trusts for specialist palliative care Delay in patient pathway due to delay in diagnostic report being received Consultant leave Other (please specify) <p>[multiple responses possible]</p>

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
13. CLINICAL TRIALS				
13.0 ogci	Entry indicator	To measure the number of patients offered and entered into trials. Required for submission to the national oesophago-gastric cancer audit.	Records the trial entry status of each patient.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review. <ul style="list-style-type: none"> Trial entry offered and accepted Trial entry offered and declined Trial entry not offered Other (e.g. no trial available)

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
14. ENDOSCOPY				
14.0 ENCDv4	Consultant code (endoscopist)	To enable endoscopic treatment analysis by consultant or nurse endoscopist responsible for the procedure performed. Required for submission to the national oesophago-gastric cancer audit.	This item relates to the consultant endoscopist who has overall endoscopic treatment responsibility for the patient and procedures performed, this may or may not be the same as the consultant (referred to)). Nationally agreed form for consultant code or Independent Nurse. It is the General Medical Council (GMC) code for the Consultant or the GP acting as a Consultant or Locum Consultant, which is the unique identifier. The nurse's Registration Number will be used to identify the Independent Nurse.	NHS Wales Data Dictionary
14.1 ENCDv4	Date on which endoscopic procedure(s) started	Therapeutic procedures required to be able to measure survival time from the start of treatment. To enable the date of first definitive treatment to be recorded. Required for submission to the national oesophago-gastric cancer audit.	The date on which the surgical procedure was performed.	
14.2 ENCDv4	Type of endoscopic procedure	Required for submission to the national oesophago-gastric cancer audit.	The main endoscopic techniques performed as part of the first therapeutic endoscopic procedure.	Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This

ALL WALES OESOPHAGO-GASTRIC CANCER MINIMUM REPORTING REQUIREMENT V2.0

Key: ENCDv4.5b = English National Cancer Dataset version 4.5b; matched data item

SPCDv1.0 = Specialist Palliative Care Dataset version 1.0; matched data item

Shaded data items refer to the data items contained within the Core Cancer Minimum Reporting Requirement V5.0

NOGCA = National Oesophago-Gastric Cancer Audit

GOCl = Oesophago-Gastric Clinical Indicator

	Reporting Data Item	Business Justification	Definition Note: Where 'NHS Wales Data Dictionary' the definition is as per the Data Dictionary.	Permissible Values
14. ENDOSCOPY [continued]				
				will be kept under review. <ul style="list-style-type: none"> • Stent insertion • Laser therapy • Argon plasma coagulation • Photodynamic therapy • Gastrostomy • Brachytherapy • Dilatation • Other